Florida Agricultural and Mechanical University

Nazarius Saah Lamango

Clivel G Charlton

Methods for cancer diagnosis, making decisions on appropriate cancer treatment, awareness of a predisposition to cancer and potential cancer prevention, and monitoring of cancer therapy by measuring the activity of PMPMEase.

Cancer diagnosis by measuring polyisoprenylated methylated protein methyl esterase activity

Methods for cancer diagnosis and treatment; in particular, methods for diagnosis and treatment of triple negative breast cancer by measuring the activity of PMPMEase.

Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R-X-A-B(R)-Y or R-X-A(R)-B-Y, where Ris preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the active site of PMPMEase and imparts hydrolysis resistance to the inhibitor, A and B are bridge atoms, and Ris a characteristic-providing substituent.

Inhibitors of polyisoprenylated methylated protein methyl esterase

A method for treatment of a mammalian neurological disease characterized by impaired neuromodulator function, the method comprises administering a therapeutically effective amount of a composition including a compound of a prenylcysteine or an analog thereof in a pharmaceutically acceptable carrier. The compound comprises a prenylcysteine or analog thereof selected from farnesylcysteine, N-acetylfarnesylcysteine, N-acetylgeranylcysteine, N-acetylfanesylcysteine, N-acetylgeranylcysteine, farnesyl-2-mercaptoethanesulfonic acid, farnesylthioacetic acid, and farnesylmercaptosuccinic acid.

Growing community of inventors

Tallahassee, FL, United States of America

Nazarius Saah Lamango